ESTRO 2025 - Abstract Book

S1305

Clinical - Lung

ESTRO 2025

From November 01, 2019 to September 05, 2023, 68 participants were randomly assigned to two groups. Twenty nine patients in Arm A and thirty two in Arm B were were available for analysis （ exclusion in 7 patients ， Figure 1 ） . The last follow-up time was November 2, 2024, with a median follow-up period of 18.6 months (range 3.7 50.7months). No significant differences were found in patient characteristics （ Table 1 ） .The progressive-free survival (PFS) in the Arm A was significantly longer than the Arm B (mean PFS: 13.0 vs.10.2 months,χ2=5.020, p=0.025,Figure 2). The Local regional PFS （ LRPFS ） rates at 6, 12, and 18 months in Arm A and Arm B were 93.1%,69.0%, and 51.2% and 71.9%, 46.9%, and 17.2%, respectively; the corresponding mean LRPFS were 20.0 months and 11.0 months, respectively (χ2=7.300, p =0.007,Figure 3).Grade 4-5 radiation toxicities were not observed in patients.

Conclusion: After MPE was limited through treatment ， primary tumor radiotherapy can significantly prolong PFS with acceptable radiation toxicity in MPE-NSCLC patient.We should pay attention to primary tumour radiotherapy in addition to systematic drug treatment for such patients.

Keywords: MPE-NSCLC; radiotherapy; progressive-free survival

745

Digital Poster AFSOS-SFRO guidelines on radiation-induced lung injury Olivier Cravereau 1 , Vivien Charzat 2 , Vincent Bourbonne 3 , Loig Vaugier 4 , Nicolas Girard 5 , Sebastien Thureau 6 , Ariane Lapierre 7 , Jean-Christophe Faivre 8 1 Department of radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France. 2 Association Francophone des Soins Oncologiques de Support, AFSOS, Bordeaux, France. 3 Radiation Oncology Department, CHU de Brest, Brest, France. 4 Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France. 5 Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France. 6 Department of Radiation Oncology and Nuclear Medicine, Centre Henri Becquerel and QuantIF LITIS, Rouen, France. 7 Department of Radiotherapy-Oncology, Lyon Sud Hospital, Pierre-Bénite, France. 8 Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France